Neuroimmunology Leadership Leverage Kyverna's neuroimmunology focus with registrational trials in stiff-person syndrome and ongoing generalized myasthenia gravis, plus a pipeline targeting multiple sclerosis and rheumatoid arthritis. Position miv-cel as a potentially first-in-class autologous CAR T option for neuroimmunology diseases with durable immune suppression and improved patient experience. Target neuroimmunology centers, rare-disease clinics, and patient advocacy groups to build awareness and align with key opinion leaders on clinical value, reimbursement, and access programs.

RA Market Expansion Rheumatoid arthritis presents a meaningful expansion path, evidenced by Phase 1 COMPARE results showing deep B-cell depletion and autoantibody suppression with durable benefit in refractory RA and an ongoing registrational RA study. Develop a go-to-market plan focused on high-volume rheumatology centers, key opinion leaders, and payer engagement to secure coverage for a potentially transformative CAR T therapy in a difficult-to-treat population.

Commercial Readiness Recent leadership hires signal commercial readiness and scale-up potential, with a CFO and Chief Commercial Officer joining in 2026. Combined with mid-size headcount and substantial revenue, Kyverna appears poised to support market access, pricing, patient access programs, and multi-geography launches. Sales teams should prioritize early access programs, payer conversations, and distribution strategy to pave the way for a commercial launch.

Competitive Differentiation Competitive positioning emphasizes a potentially first-in-class label in neuroimmunology and a differentiated autologous CD19 CAR T approach that aims for deep and durable disease control. Communicate this differentiation to clinicians and payers, explore strategic partnerships or co-development deals, and build reimbursement narratives around reduced long-term disease burden and durable response in autoimmune indications.

Collaboration Opportunities IITs and KYSA programs in MS and RA indicate ongoing collaboration with academic centers and a path to expanding indications through real-world evidence. Proactively pursue investigator partnerships, data-sharing arrangements, and post-market surveillance opportunities to strengthen evidence packages for payers, widen the network of referral centers, and accelerate access for patients who could benefit from CAR T therapies in autoimmune diseases.